Caitlin W Hicks1, Shalini Selvarajah2, Nestoras Mathioudakis3, Ronald E Sherman4, Kathryn F Hines5, James H Black1, Christopher J Abularrage6. 1. Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD. 2. Center for Surgical Trials and Outcomes Research, Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD. 3. Division of Endocrinology & Metabolism, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD; Diabetic Foot and Wound Service, The Johns Hopkins Hospital, Baltimore, MD. 4. Diabetic Foot and Wound Service, The Johns Hopkins Hospital, Baltimore, MD; Department of Orthopedic Surgery, The Johns Hopkins Hospital, Baltimore, MD. 5. Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD; Diabetic Foot and Wound Service, The Johns Hopkins Hospital, Baltimore, MD. 6. Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD; Center for Surgical Trials and Outcomes Research, Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD; Diabetic Foot and Wound Service, The Johns Hopkins Hospital, Baltimore, MD. Electronic address: cabular1@jhmi.edu.
Abstract
BACKGROUND: Costs related to diabetic foot ulcer (DFU) care are greater than $1 billion annually and rising. We sought to describe the impact of diabetes mellitus (DM) on foot ulcer admissions in the United States, and to investigate potential explanations for rising hospital costs. METHODS: The Nationwide Inpatient Sample (2005-2010) was queried using International Classification of Diseases, 9th Revision (ICD-9) codes for a primary diagnosis of foot ulceration. Multivariable analyses were used to compare outcomes and per-admission costs among patients with foot ulceration and DM versus non-DM. RESULTS: In total, 962,496 foot ulcer patients were admitted over the study period. The overall rate of admissions was relatively stable over time, but the ratio of DM versus non-DM admissions increased significantly (2005: 10.2 vs. 2010: 12.7; P < 0.001). Neuropathy and infection accounted for 90% of DFU admissions, while peripheral vascular disease accounted for most non-DM admissions. Admissions related to infection rose significantly among DM patients (2005: 39,682 vs. 2010: 51,660; P < 0.001), but remained stable among non-DM patients. Overall, DM accounted for 83% and 96% of all major and minor amputations related to foot ulcers, respectively, and significantly increased cost of care (DM: $1.38 vs. non-DM: $0.13 billion/year; P < 0.001). Hospital costs per DFU admission were significantly higher for patients with infection compared with all other causes ($11,290 vs. $8,145; P < 0.001). CONCLUSIONS: Diabetes increases the incidence of foot ulcer admissions by 11-fold, accounting for more than 80% of all amputations and increasing hospital costs more than 10-fold over the 5 years. The majority of these costs are related to the treatment of infected foot ulcers. Education initiatives and early prevention strategies through outpatient multidisciplinary care targeted at high-risk populations are essential to preventing further increases in what is already a substantial economic burden.
BACKGROUND: Costs related to diabetic foot ulcer (DFU) care are greater than $1 billion annually and rising. We sought to describe the impact of diabetes mellitus (DM) on foot ulcer admissions in the United States, and to investigate potential explanations for rising hospital costs. METHODS: The Nationwide Inpatient Sample (2005-2010) was queried using International Classification of Diseases, 9th Revision (ICD-9) codes for a primary diagnosis of foot ulceration. Multivariable analyses were used to compare outcomes and per-admission costs among patients with foot ulceration and DM versus non-DM. RESULTS: In total, 962,496 foot ulcerpatients were admitted over the study period. The overall rate of admissions was relatively stable over time, but the ratio of DM versus non-DM admissions increased significantly (2005: 10.2 vs. 2010: 12.7; P < 0.001). Neuropathy and infection accounted for 90% of DFU admissions, while peripheral vascular disease accounted for most non-DM admissions. Admissions related to infection rose significantly among DMpatients (2005: 39,682 vs. 2010: 51,660; P < 0.001), but remained stable among non-DMpatients. Overall, DM accounted for 83% and 96% of all major and minor amputations related to foot ulcers, respectively, and significantly increased cost of care (DM: $1.38 vs. non-DM: $0.13 billion/year; P < 0.001). Hospital costs per DFU admission were significantly higher for patients with infection compared with all other causes ($11,290 vs. $8,145; P < 0.001). CONCLUSIONS:Diabetes increases the incidence of foot ulcer admissions by 11-fold, accounting for more than 80% of all amputations and increasing hospital costs more than 10-fold over the 5 years. The majority of these costs are related to the treatment of infected foot ulcers. Education initiatives and early prevention strategies through outpatient multidisciplinary care targeted at high-risk populations are essential to preventing further increases in what is already a substantial economic burden.
Authors: Dean T Williams; Muhammad U Majeed; Guy Shingler; Mohammed J Akbar; Diane G Adamson; Christopher J Whitaker Journal: Ann Vasc Surg Date: 2012-04-12 Impact factor: 1.466
Authors: David L Cull; Ginger Manos; Michael C Hartley; Spence M Taylor; Eugene M Langan; John F Eidt; Brent L Johnson Journal: J Vasc Surg Date: 2014-10-03 Impact factor: 4.268
Authors: Mohamad A Hussain; Mohammed Al-Omran; Konrad Salata; Atul Sivaswamy; Thomas L Forbes; Naveed Sattar; Badr Aljabri; Ahmed Kayssi; Subodh Verma; Charles de Mestral Journal: CMAJ Date: 2019-09-03 Impact factor: 8.262
Authors: Andrew S Kimball; Frank M Davis; Aaron denDekker; Amrita D Joshi; Matthew A Schaller; Jennifer Bermick; Xianying Xing; Charles F Burant; Andrea T Obi; Dylan Nysz; Scott Robinson; Ron Allen; Nicholas W Lukacs; Peter K Henke; Johann E Gudjonsson; Bethany B Moore; Steve L Kunkel; Katherine A Gallagher Journal: Immunity Date: 2019-07-23 Impact factor: 31.745
Authors: Irvin Oh; Gowrishankar Muthukrishnan; Mark J Ninomiya; James D Brodell; Benjamin L Smith; Charles C Lee; Steven R Gill; Christopher A Beck; Edward M Schwarz; John L Daiss Journal: Infect Immun Date: 2018-11-20 Impact factor: 3.441
Authors: Chris A Anthony; John E Femino; Aaron C Miller; Linnea A Polgreen; Edward O Rojas; Shelby L Francis; Alberto M Segre; Philip M Polgreen Journal: Iowa Orthop J Date: 2020
Authors: Sean M Stainton; Marguerite L Monogue; Arlinda Baummer-Carr; Ashley K Shepard; James F Nugent; Joseph L Kuti; David P Nicolau Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: Hannah Forde; Sarah Wrigley; Liam Tomas O'Murchadha; Lyn Cusack; Sinead Casserly; Daragh Moneley; James Walsh; Diarmuid Smith Journal: Ir J Med Sci Date: 2019-10-24 Impact factor: 1.568